312 related articles for article (PubMed ID: 22252140)
21. Ex vivo and in vitro testis and ovary explants: utility for identifying steroid biosynthesis inhibitors and comparison to a Tier I screening battery.
Powlin SS; Cook JC; Novak S; O'Connor JC
Toxicol Sci; 1998 Nov; 46(1):61-74. PubMed ID: 9928669
[TBL] [Abstract][Full Text] [Related]
22. FIFRA Subdivision F testing Guidelines: are these tests adequate to detect potential hormonal activity for crop protection chemicals? Federal Insecticide, Fungicide, and Rodenticide Act.
Stevens JT; Tobia A; Lamb JC; Tellone C; O'Neal F
J Toxicol Environ Health; 1997 Apr; 50(5):415-31. PubMed ID: 9140462
[TBL] [Abstract][Full Text] [Related]
23. Relevance of in vitro neurotoxicity testing for regulatory requirements: challenges to be considered.
Bal-Price AK; Hogberg HT; Buzanska L; Coecke S
Neurotoxicol Teratol; 2010; 32(1):36-41. PubMed ID: 19150401
[TBL] [Abstract][Full Text] [Related]
24. Organ slices for the evaluation of human drug toxicity.
Vickers AE; Fisher RL
Chem Biol Interact; 2004 Nov; 150(1):87-96. PubMed ID: 15522263
[TBL] [Abstract][Full Text] [Related]
25. In vivo erythrocyte micronucleus assay III. Validation and regulatory acceptance of automated scoring and the use of rat peripheral blood reticulocytes, with discussion of non-hematopoietic target cells and a single dose-level limit test.
Hayashi M; MacGregor JT; Gatehouse DG; Blakey DH; Dertinger SD; Abramsson-Zetterberg L; Krishna G; Morita T; Russo A; Asano N; Suzuki H; Ohyama W; Gibson D;
Mutat Res; 2007 Feb; 627(1):10-30. PubMed ID: 17157053
[TBL] [Abstract][Full Text] [Related]
26. In silico toxicology for the pharmaceutical sciences.
Valerio LG
Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
[TBL] [Abstract][Full Text] [Related]
27. Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments.
Astashkina A; Grainger DW
Adv Drug Deliv Rev; 2014 Apr; 69-70():1-18. PubMed ID: 24613390
[TBL] [Abstract][Full Text] [Related]
28. The significance of mitochondrial toxicity testing in drug development.
Dykens JA; Will Y
Drug Discov Today; 2007 Sep; 12(17-18):777-85. PubMed ID: 17826691
[TBL] [Abstract][Full Text] [Related]
29. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
[TBL] [Abstract][Full Text] [Related]
30. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
[TBL] [Abstract][Full Text] [Related]
31. Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens.
Caldwell GW
Curr Opin Drug Discov Devel; 2000 Jan; 3(1):30-41. PubMed ID: 19649835
[TBL] [Abstract][Full Text] [Related]
32. Predictive models of prenatal developmental toxicity from ToxCast high-throughput screening data.
Sipes NS; Martin MT; Reif DM; Kleinstreuer NC; Judson RS; Singh AV; Chandler KJ; Dix DJ; Kavlock RJ; Knudsen TB
Toxicol Sci; 2011 Nov; 124(1):109-27. PubMed ID: 21873373
[TBL] [Abstract][Full Text] [Related]
33. A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery.
Evensen L; Micklem DR; Link W; Lorens JB
Cytometry A; 2010 Jan; 77(1):41-51. PubMed ID: 19834964
[TBL] [Abstract][Full Text] [Related]
34. Replacement of in vivo acute oral toxicity studies by in vitro cytotoxicity methods: opportunities, limits and regulatory status.
Ukelis U; Kramer PJ; Olejniczak K; Mueller SO
Regul Toxicol Pharmacol; 2008 Jun; 51(1):108-18. PubMed ID: 18362045
[TBL] [Abstract][Full Text] [Related]
35. Screening and evaluation of anticancer agents.
Zee-Cheng RK; Cheng CC
Methods Find Exp Clin Pharmacol; 1988 Feb; 10(2):67-101. PubMed ID: 3283480
[TBL] [Abstract][Full Text] [Related]
36. Improvement of in vivo genotoxicity assessment: combination of acute tests and integration into standard toxicity testing.
Rothfuss A; Honma M; Czich A; Aardema MJ; Burlinson B; Galloway S; Hamada S; Kirkland D; Heflich RH; Howe J; Nakajima M; O'Donovan M; Plappert-Helbig U; Priestley C; Recio L; Schuler M; Uno Y; Martus HJ
Mutat Res; 2011 Aug; 723(2):108-20. PubMed ID: 21182982
[TBL] [Abstract][Full Text] [Related]
37. Hydrogel tissue construct-based high-content compound screening.
Lam V; Wakatsuki T
J Biomol Screen; 2011 Jan; 16(1):120-8. PubMed ID: 21123829
[TBL] [Abstract][Full Text] [Related]
38. Increasing throughput in lead optimization in vivo toxicity screens.
Meador V; Jordan W; Zimmermann J
Curr Opin Drug Discov Devel; 2002 Jan; 5(1):72-8. PubMed ID: 11865675
[TBL] [Abstract][Full Text] [Related]
39. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
Whitebread S; Hamon J; Bojanic D; Urban L
Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
[TBL] [Abstract][Full Text] [Related]
40. 2D and 3D cell microarrays in pharmacology.
Gidrol X; Fouqué B; Ghenim L; Haguet V; Picollet-D'hahan N; Schaack B
Curr Opin Pharmacol; 2009 Oct; 9(5):664-8. PubMed ID: 19520607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
